FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954732206> ?p ?o ?g. }

• W2954732206 endingPage "3036" @default.
• W2954732206 startingPage "3036" @default.
• W2954732206 abstract "Abstract Treatment with bromodomain and extra-terminal protein inhibitor (BETi) reduces in vivo AML cell burden, inducing clinical remissions in AML. Yet, resistance to BETi treatment develops uniformly. Here, following at least 10 exposures of secondary (s) AML control (parental) SET2 and HEL92.1.7 cells to 1.0 µM of the BETi OTX015 for 48 hours followed by full recovery, we generated BETi persister-resistant (BETi-P/R) SET2-P/R and HEL-P/R cells. These cells showed &gt; 10-fold resistance to OTX015 and cross-resistance to other BETis. Compared to the controls, SET2-P/R and HEL-P/R cells lacked additional genetic alterations or altered levels of TRIM33, SPOP, DUB3 or phosphorylated BRD4 (previously described mechanisms of BETi-resistance). However, SET2-P/R and HEL-P/R cells demonstrated significantly higher nuclear levels of β-catenin, the transcription factor TCF7L2 and adaptor protein TBL1X (TBL1), associated with increased expression of TCF7L2 targets, including c-Myc, Cyclin D1, TERT and Survivin. ATAC-Seq and ChIP-Seq (H3K27Ac mark) analyses showed significant gain of peaks and active enhancers in HEL-P/R over HEL92.1.7 cells, with enrichment of STAT5, MYC, PU.1 and GATA2 binding sites, as well as newly gained peaks in the enhancers of JAK1/2, RUNX1, PU.1, MYC, BCL2L1 and CTNNB1. RNA-Seq analysis showed significant increase/decrease in mRNA expressions (340/247), with induction of gene-sets involving MYC/MAX, STAT5, NFkB and TCF7L2 targets. QPCR and Western analyses confirmed increase in the mRNA and protein levels of TCF7L2, c-Myc, Survivin and PIM1 in HEL-P/R over HEL92.1.7 cells. Also, confocal microscopy demonstrated increased binding of β-catenin with TBL1 and TCF7L2 in the nucleus in BETi-P/R sAML cells. β-catenin inhibitor BC2059, which disrupts binding of nuclear β-catenin with TBL1 and TCF7L2 and depletes β-catenin levels, exerted similar lethality in BETi-P/R sAML and control sAML cells. Both shRNA-mediated knockdown of BRD4 and BRD4-PROTAC (proteolysis-targeting chimera) ARV-771 (Arvinas, Inc.), which degrades BRD4/3/2, induced similar level of apoptosis in BETi-P/R and control sAML cells. Co-treatment with ARV-771 and BC2059 synergistically induced lethality in BETi-P/R sAML cells as well as in patient-derived, CD34+ sAML BPCs (combination indices &lt; 1.0). This was associated with marked attenuation of c-Myc, TCF4, Survivin, CDK6, PIM1 and Bcl-xL levels. Also, compared to each agent alone, in vivo treatment with ARV-771 (30 mg/kg SQ daily x 5, per week) and BC2059 (30 mg/kg IP BIW, per week) for 3 weeks, significantly reduced sAML burden and improved survival of NSG mice engrafted with HEL-P/R cells (p &lt; 0.01). Thus, increased levels and activity of β-catenin-TCF7L2-MYC axis is mechanistically responsible for BETi-P/R, and co-targeting with BRD4 degrader and β-catenin-TCF7L2 inhibitor is a promising therapeutic strategy against BETi-P/R sAML BPCs. Citation Format: Dyana T. Saenz, Warren C. Fiskus, Taghi Manshouri, Christopher P. Mill, Steve Horrigan, Raffaella Soldi, Joseph D. Khoury, Sunil Sharma, Srdan Verstovesek, Kapil N. Bhalla. BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3036." @default.
• W2954732206 created "2019-07-12" @default.
• W2954732206 creator A5000534025 @default.
• W2954732206 creator A5008109253 @default.
• W2954732206 creator A5013802454 @default.
• W2954732206 creator A5024633440 @default.
• W2954732206 creator A5061012285 @default.
• W2954732206 creator A5061728022 @default.
• W2954732206 creator A5067213000 @default.
• W2954732206 creator A5067678169 @default.
• W2954732206 creator A5079069209 @default.
• W2954732206 creator A5088881526 @default.
• W2954732206 date "2019-07-01" @default.
• W2954732206 modified "2023-10-14" @default.
• W2954732206 title "Abstract 3036: BRD4 degrader and inhibitor of beta catenin-TCF7L2 are synergistically active against human AML cells resistant to BET inhibitor" @default.
• W2954732206 doi "https://doi.org/10.1158/1538-7445.am2019-3036" @default.
• W2954732206 hasPublicationYear "2019" @default.
• W2954732206 type Work @default.
• W2954732206 sameAs 2954732206 @default.
• W2954732206 citedByCount "0" @default.
• W2954732206 crossrefType "journal-article" @default.
• W2954732206 hasAuthorship W2954732206A5000534025 @default.
• W2954732206 hasAuthorship W2954732206A5008109253 @default.
• W2954732206 hasAuthorship W2954732206A5013802454 @default.
• W2954732206 hasAuthorship W2954732206A5024633440 @default.
• W2954732206 hasAuthorship W2954732206A5061012285 @default.
• W2954732206 hasAuthorship W2954732206A5061728022 @default.
• W2954732206 hasAuthorship W2954732206A5067213000 @default.
• W2954732206 hasAuthorship W2954732206A5067678169 @default.
• W2954732206 hasAuthorship W2954732206A5079069209 @default.
• W2954732206 hasAuthorship W2954732206A5088881526 @default.
• W2954732206 hasConcept C104317684 @default.
• W2954732206 hasConcept C111936080 @default.
• W2954732206 hasConcept C11960822 @default.
• W2954732206 hasConcept C153911025 @default.
• W2954732206 hasConcept C185592680 @default.
• W2954732206 hasConcept C190283241 @default.
• W2954732206 hasConcept C199835354 @default.
• W2954732206 hasConcept C2775975398 @default.
• W2954732206 hasConcept C2776414213 @default.
• W2954732206 hasConcept C2779391668 @default.
• W2954732206 hasConcept C2780862049 @default.
• W2954732206 hasConcept C2781018059 @default.
• W2954732206 hasConcept C29537977 @default.
• W2954732206 hasConcept C41091548 @default.
• W2954732206 hasConcept C43821964 @default.
• W2954732206 hasConcept C502942594 @default.
• W2954732206 hasConcept C54355233 @default.
• W2954732206 hasConcept C55493867 @default.
• W2954732206 hasConcept C74401373 @default.
• W2954732206 hasConcept C81885089 @default.
• W2954732206 hasConcept C86339819 @default.
• W2954732206 hasConcept C86803240 @default.
• W2954732206 hasConcept C95444343 @default.
• W2954732206 hasConcept C98175054 @default.
• W2954732206 hasConceptScore W2954732206C104317684 @default.
• W2954732206 hasConceptScore W2954732206C111936080 @default.
• W2954732206 hasConceptScore W2954732206C11960822 @default.
• W2954732206 hasConceptScore W2954732206C153911025 @default.
• W2954732206 hasConceptScore W2954732206C185592680 @default.
• W2954732206 hasConceptScore W2954732206C190283241 @default.
• W2954732206 hasConceptScore W2954732206C199835354 @default.
• W2954732206 hasConceptScore W2954732206C2775975398 @default.
• W2954732206 hasConceptScore W2954732206C2776414213 @default.
• W2954732206 hasConceptScore W2954732206C2779391668 @default.
• W2954732206 hasConceptScore W2954732206C2780862049 @default.
• W2954732206 hasConceptScore W2954732206C2781018059 @default.
• W2954732206 hasConceptScore W2954732206C29537977 @default.
• W2954732206 hasConceptScore W2954732206C41091548 @default.
• W2954732206 hasConceptScore W2954732206C43821964 @default.
• W2954732206 hasConceptScore W2954732206C502942594 @default.
• W2954732206 hasConceptScore W2954732206C54355233 @default.
• W2954732206 hasConceptScore W2954732206C55493867 @default.
• W2954732206 hasConceptScore W2954732206C74401373 @default.
• W2954732206 hasConceptScore W2954732206C81885089 @default.
• W2954732206 hasConceptScore W2954732206C86339819 @default.
• W2954732206 hasConceptScore W2954732206C86803240 @default.
• W2954732206 hasConceptScore W2954732206C95444343 @default.
• W2954732206 hasConceptScore W2954732206C98175054 @default.
• W2954732206 hasIssue "13_Supplement" @default.
• W2954732206 hasLocation W29547322061 @default.
• W2954732206 hasOpenAccess W2954732206 @default.
• W2954732206 hasPrimaryLocation W29547322061 @default.
• W2954732206 hasRelatedWork W1948889165 @default.
• W2954732206 hasRelatedWork W1967180140 @default.
• W2954732206 hasRelatedWork W2060484997 @default.
• W2954732206 hasRelatedWork W2511084206 @default.
• W2954732206 hasRelatedWork W2530512275 @default.
• W2954732206 hasRelatedWork W2551897003 @default.
• W2954732206 hasRelatedWork W2884184577 @default.
• W2954732206 hasRelatedWork W2896912519 @default.
• W2954732206 hasRelatedWork W2954732206 @default.
• W2954732206 hasRelatedWork W2955113018 @default.
• W2954732206 hasVolume "79" @default.
• W2954732206 isParatext "false" @default.
• W2954732206 isRetracted "false" @default.
• W2954732206 magId "2954732206" @default.
• W2954732206 workType "article" @default.